Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Haven, an sun protectant product that reduces plant stress and dehydration; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Further, it provides Stargus and Amplitude, a biofungicide for improving plant health. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-750-2800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.22 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable
Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions
What is Marrone Bio Innovations' stock symbol?
Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."
How were Marrone Bio Innovations' earnings last quarter?
Marrone Bio Innovations Inc (NASDAQ:MBII) announced its quarterly earnings data on Thursday, March, 14th. The basic materials company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.05). The basic materials company had revenue of $5.72 million for the quarter, compared to analysts' expectations of $5.03 million. Marrone Bio Innovations had a negative return on equity of 110.20% and a negative net margin of 95.26%. View Marrone Bio Innovations' Earnings History.
When is Marrone Bio Innovations' next earnings date?
What price target have analysts set for MBII?
2 analysts have issued 1-year price targets for Marrone Bio Innovations' stock. Their predictions range from $2.50 to $3.00. On average, they anticipate Marrone Bio Innovations' share price to reach $2.75 in the next year. This suggests a possible upside of 70.8% from the stock's current price. View Analyst Price Targets for Marrone Bio Innovations.
What is the consensus analysts' recommendation for Marrone Bio Innovations?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marrone Bio Innovations.
What are Wall Street analysts saying about Marrone Bio Innovations stock?
Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
- 1. National Securities analysts commented, "Strong First Half of 2019 Could Be the Catalyst Shareholders Need. With shares hitting a resistance level of roughly $1.60 several times over the past six months, we believe a strong performance over the next two quarters could be the catalyst shares need to break through this level.
Strong Second Half Of 2018 A Sign of What Is To Come. Coming off a weak first half of 2018 which saw revenue decline by 5%, MBII ended 2018 strong with 47% growth in the second half of the year. We believe this momentum will continue into the first half of 2019.
TTM Numbers Poised for Meaningful Improvement Over Next Two Quarters. We model TTM revenue growth of 50% through the first half of 2019. Should results fall in line with our estimates, we believe MBII shares will look increasingly attractive to quantitative and fundamental investors alike.
Maturation Of The Sales Force Set To Deliver. In late 2017, MBII had a turnover of 75% of its sales force. With the vacancies filled in early 2018, much of the sales force is now beginning its second year with the company. We believe the natural maturation of this group will be a catalyst for meaningful growth in 2019 and 2020.
A New Fiscal Year Never Looked So Good. With a healthy balance sheet, stable sales force, ramping of a major seed treatment contract and strong macro tailwinds, we believe MBII enters 2019 in a better position than it has enjoyed since its IPO in 2013." (4/25/2019)
- 2. According to Zacks Investment Research, "Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. " (11/29/2018)
- 3. HC Wainwright analysts commented, "We are lowering our price target on MBII to $2.50, from $3.50 previously, driven by: (1) effect of salesforce attrition, experienced earlier in 2018, that has continued to negatively impact the pace of topline revenue growth; (2) slower than expected regulatory approval process for the company’s bioinsecticides, biofubgicides, and biopesticides.; and (3) longer than expected sales cycles. We are now taking a slightly more conservative stance on our forward projections for MBII, resulting in the lowered price target. Please see the valuation section of this note for more details. 3Q18 results overview. 2018, MBII reported revenues of $5.4M for the quarter (28.6% YoY increase). Gross margins were 48.3% for the quarter, compared to 40.9% in the year ago period." (11/14/2018)
Has Marrone Bio Innovations been receiving favorable news coverage?
News coverage about MBII stock has trended negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Marrone Bio Innovations earned a news impact score of -2.2 on InfoTrie's scale. They also gave media stories about the basic materials company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Marrone Bio Innovations' key competitors?
Some companies that are related to Marrone Bio Innovations include Calyxt (CLXT), American Vanguard (AVD), CVR Partners (UAN), Wynnstay Group (WYN), Evogene (EVGN), SenesTech (SNES), Arcadia Biosciences (RKDA), Eden Research (EDEN), China Green Agriculture (CGA), Bion Environmental Technologies (BNET), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), Monsanto (MON), Syngenta (SYT) and Terra Nitrogen (TNH).
What other stocks do shareholders of Marrone Bio Innovations own?
Who are Marrone Bio Innovations' key executives?
Marrone Bio Innovations' management team includes the folowing people:
- Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
- Mr. James B. Boyd, Pres & CFO (Age 66)
- Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
- Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
- Andre Trepanier, Director of Marketing
How do I buy shares of Marrone Bio Innovations?
Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marrone Bio Innovations' stock price today?
One share of MBII stock can currently be purchased for approximately $1.61.
How big of a company is Marrone Bio Innovations?
Marrone Bio Innovations has a market capitalization of $178.21 million and generates $21.22 million in revenue each year. The basic materials company earns $-20,210,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
What is Marrone Bio Innovations' official website?
How can I contact Marrone Bio Innovations?
Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]
MarketBeat Community Rating for Marrone Bio Innovations (NASDAQ MBII)
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
